Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Granite Bio
Deal Size : $100.0 million
Deal Type : Series B Financing
Granite Bio Debuts with $100 Million of Capital
Details : The financing aims to fund the development of Granite pipeline including GRT-001, it depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. It is being evaluated for IBD.
Product Name : GRT-001
Product Type : Antibody
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Granite Bio
Deal Size : $100.0 million
Deal Type : Series B Financing
Lead Product(s) : PJS-539
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PJS-539 is a potent, once daily, oral pill that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses to treat COVID-19.
Product Name : PJS-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : PJS-539
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
